Turn Therapeutics Inc.
NASDAQ:TTRX · NASDAQ Global Select
-$0.17 today
Vol 0.03M · Avg 0.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-68.2%
avg -581.4%
ROIC
-94.4%
avg -124.5%
ROA
-26.3%
avg -75.5%
Analysis
ROA is currently the strongest return metric at -26.3% versus its period average of -75.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bradley E. Burnam | Founder, Chief Executive Officer & Director | $465,740.00 | — | 46 | — | — |
Zuraiz Chaudhary | Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer | $365,306.00 | — | 30 | — | — |
Neilesh Shailesh Ghodadra | Chief Medical Officer & Director | — | — | 45 | — | — |
Mohammed Zubair | Controller | — | — | — | — | — |
Stephen Hahn FASTRO | Executive Clinical & Regulatory Lead | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
$343.76M
Opus Genetics, Inc.
NASDAQ:IRD
$335.63M
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
$229.74M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$150.61M
Agenus Inc.
NASDAQ:AGEN
$123.47M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$104.73M
Seer, Inc.
NASDAQ:SEER
$94.57M
Anixa Biosciences, Inc.
NASDAQ:ANIX
$89.82M
Tevogen Bio Holdings Inc.
TVGN
$43.63M
VistaGen Therapeutics, Inc.
VTGN
$22.67M
Who manages TTRX?
Turn Therapeutics Inc. (TTRX) lists 5 active executives. The top listed executive is Neilesh Shailesh Ghodadra, Chief Medical Officer & Director.
Explore More
Continue the stock analysis
Jump to another research area for this company.